Member Directory - Pharmaceutical Advisory Board
Primary tabs
Chair: Charles Flexner
Objectives:
- Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
- Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention. |
After his medicinal chemistry PhD and a Marie Curie Fellowship at Utrecht University, Lluis Ballell Pagès joined GlaxoSmithKline in 2005 to lead different preclinical infectious diseases projects and setup the Open Lab.. Conflict of Interest: Receives salary from, and has an ownership interest in, Johnson & Johnson. |